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AbstrACt
Introduction Valid and low-cost quality assessment 
tools examining care quality are not readily available. 
The unannounced standardised patient (USP), the gold 
standard for assessing quality, is costly to implement while 
the validity of clinical vignettes, as a low-cost alternative, 
has been challenged. Computerised virtual patients (VPs) 
create high-fidelity and interactive simulations of doctor-
patient encounters which can be easily implemented 
via smartphone at low marginal cost. Our study aims to 
develop and validate smartphone-based VP as a quality 
assessment tool for primary care, compared with USP.
Methods and analysis The study will be implemented 
in primary health centres (PHCs) in rural areas of seven 
Chinese provinces, and physicians practicing at township 
health centres and village clinics will be our study 
population. The development of VPs involves three steps: 
(1) identifying 10 VP cases that can best represent rural 
PHCs’ work, (2) designing each case by a case-specific 
development team and (3) developing corresponding 
quality scoring criteria. After being externally reviewed 
for content validity, these VP cases will be implemented 
on a smartphone-based platform and will be tested for 
feasibility and face validity. This smartphone-based VP tool 
will then be validated for its criterion validity against USP 
and its reliability (ie, internal consistency and stability), 
with 1260 VP/USP-clinician encounters across the seven 
study provinces for all 10 VP cases.
Ethics and dissemination Sun Yat-sen University: No. 
2017-007. Study findings will be published and tools 
developed will be freely available to low-income and 
middle-income countries for research purposes.
IntroduCtIon 
Universal health coverage (UHC) is a para-
mount goal of health system development for 
countries at all income levels.1 The achieve-
ment of UHC is not possible without primary 
healthcare services,1 which ensure integrated 
care close to the population they serve and 
link to the health-related sustainable devel-
opment goals.2 However, service coverage 
alone cannot improve health outcomes if the 
quality of care is poor. Despite efforts devoted 
to improving healthcare services, there is a 
lack of scientific evidence on the quality of 
primary healthcare in resource-poor settings, 
particularly of low-income and middle-in-
come countries (LMICs).3–6 
This scarcity of evidence may partially result 
from the limited availability of valid, low cost 
and easy-to-implement quality assessment 
tools.7 As defined by Donabedian’s frame-
work, healthcare quality can be evaluated by 
the structure of care (eg, staff, equipment), 
the process of care delivery (eg, doctor-patient 
interactions) and health outcomes (eg, death 
or complications).8 Increasingly, process 
measures are being used, because of their 
advantages in terms of frequent and timely 
evaluation and the usefulness in improving 
practice.9 10 The ‘gold standard’ of assessing 
process is the unannounced standardised 
patient (USP), namely a trained actor who 
simulates the symptoms, signs and emotions 
of a real patient in a standardised fashion and 
presents himself or herself unannounced 
to clinics to assess care quality.11 USP can 
reduce recall bias better than patient exit 
interviews, minimise the Hawthorne effect 
strengths and limitations of this study
 ► Developing and validating smartphone-based vir-
tual   patient (VP) as a quality assessment tool for 
research and routine use in rural primary healthcare 
centres.
 ► Following an evidence-based approach to develop 
VP cases and scoring criteria.
 ► Systematically validating the VP assessment tool via 
a cross-national multicentre study.
 ► The extent to which the VP assessment will reflect 
practitioners’ real clinical practice needs to be 
verified.
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that inevitably occurs in direct observation and allow for 
comparisons between users as case-mix and patient-mix 
are controlled.3 9 11 Nonetheless, the USP can only portray 
a limited number of conditions without obvious physio-
logical symptoms and risk of invasive examinations. Also, 
training and implementation of USP can require substan-
tial personnel and resources, making USP impractical for 
large-scale and routine quality assessment.12 13
As an alternative, clinical vignettes or case simula-
tions have been widely used as a low-cost and convenient 
method for assessing care quality.9 14 Vignettes have been 
implemented in a paper-and-pencil form,9 presented by an 
enumerator5 and streamlined by a computer.14 Evidence 
of the validity of vignettes in assessing the quality of 
patient care is mixed. Some studies showed that vignettes 
reflect clinicians’ competency (know-how) rather than 
their actual behaviours and can lead to overestimation of 
clinical performance.9 15 By contrast, other studies found 
that vignette-based results, particularly those streamlined 
by computer, are quite close to the USP-based assess-
ment.14 16 The enumerator-administered vignette is similar 
to the announced standardised patient and thus is expen-
sive and difficult to implement.5 A computerised vignette 
can be interactive and can more realistically represent the 
complexity of a clinical encounter.14 As a further improve-
ment on computerised vignettes,14 smartphone virtual 
patients (VPs) create high-fidelity, visualised and interac-
tive simulations that replicate clinical complexity and can 
be easily implemented at a low marginal cost.17 Although 
VPs cannot remove the Hawthorne effect, their advanced 
features may reduce the measurement gap between 
competency and actual practice.10 14 While VPs have been 
used in medical education to train and test clinical skills 
such as clinical reasoning, diagnosis and therapeutic deci-
sions,18 their relative validity as a measure of quality of 
care has yet to be studied. Strengths and limitations of the 
abovementioned three methods are compared in table 1.
In the present study, we propose to adapt smart-
phone-based VP for medical education as a quality-of-care 
assessment tool, given its advantages in (1) standardisa-
tion (VPs are highly standardised, ensuring consistent 
assessments across users), (2) flexibility (assessments can 
be delivered by smartphones for multiple users at any 
time, anywhere, providing data connectivity is available), 
(3) scalability (VPs can be modified to demonstrate and 
assess almost any clinical conditions with low marginal 
cost) and (4) training (VPs can also be used as a training 
tool to improve healthcare quality and thus to address 
the ‘so what’ question after quality assessment). These 
characteristics may especially benefit quality assessment 
and improvement in rural primary care settings, where 
communities are geographically scattered and difficult to 
reach and manage.
Therefore, our study aims to develop and validate 
smartphone-based VPs against USPs as a quality assessment 
tool that can be used both for research purposes and 
for routine evaluation of quality of primary healthcare 
provided by primary health centres (PHCs) in rural areas. 
To maximise its validity,14 we will systematically construct 
high-fidelity VP cases to reflect clinical complexity in rural 
PHC contexts with real-time patient-doctor interactions 
and temporal constraints and use evidence-based quality 
scoring criteria; additionally, we will make the VP-based 
test anonymous to minimise the Hawthorne effect. The 
initial phase of the study will mainly focus on rural China, 
while the ultimate goal is to develop and validate tools 
that can have a broad application in other LMICs.
MEthods And AnAlysIs
study setting
The validation study will be implemented in the outpa-
tient setting of rural PHCs (ie, township health centres 
and village clinics) in seven Chinese provinces (Guizhou, 
Table 1 Strengths and limitations of quality assessment measures
Process measure of 
quality Strengths Limitations Assessment level
Unannounced standardised 
patient
Standardised, controlling for case-mix and 
patient- mix;
Unannounced, no Hawthorne effect (if not be 
detected);
Reduced recall bias
Expensive
Limited medical conditions
First-visit bias
Selection bias if informed 
consent is required
Action (Do)
Gold standard
Clinical vignettes Cost-effective;
Suitable for large scale and cross-system 
comparison;
Covering all illnesses;
Accounting for case-mix and patient-mix.
Hawthorne effect
Selection bias
Competence (Know 
how)
Overestimating 
care quality (best 
answers) or similar
Virtual patients Interactive
Real-time response and automatic record
Highly standardised
Scalability and low marginal cost
Efficient delivery: anytime, anywhere Suitable 
for large scale study
Hawthorne effect
Selection bias
High cost in initial 
development
Performance (Show 
how)
?
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Sichuan, Gansu, Inner Mongolia, Shaanxi, Hunan and 
Guangdong). We are selecting these provinces to reflect 
the five strata of low-to-high life-expectancies and various 
burden-of-disease patterns in China19 and to contrast 
geographic regions with diverse ethnic composition, 
including southwest mountainous regions, the northern 
plateau, the middle inland region and southeast coastal 
areas (figure 1). Our study targets township health centres 
and village clinics because they provide the majority of 
primary healthcare in rural China.20 21 At township health 
centres, primary healthcare is delivered by a workforce 
including licensed/unlicensed physicians, licensed/unli-
censed assistant physicians and registered nurses, while 
at village clinics, services are mainly delivered by one 
full-time or part-time ‘village doctor’ who is a clinician 
with rudimentary medical training.20 22 23 The outpatient 
setting is chosen due to the small number of inpatient 
cases in township health centres and village clinics. Study 
recruitment is expected to start from June 2018.
VP case development
VP case selection
We intend to select 10 cases that together can represent 
the work of rural PHCs. The selection of the VP cases will 
be based on the following criteria: (1) high frequency of 
clinical encounters in the primary care settings in rural 
areas and/or (2) association with significant disease 
burden; (3) representation of the major areas of work 
of PHCs in rural China overall (eg, public health service 
delivery, chronic disease management, infectious disease 
control, health education and patient-centred care) and 
(4) suitability for the USP methodology (eg, no obvious 
physiological signs, low risk for invasive tests) for the 
sake of criterion validation in the current study. A case 
selection committee will comprise a range of stake-
holders, including physicians, public health practitioners, 
policy-makers and members of the research team. Based 
on the literature review, the research team will prepare 
a shortlist of the 30 most frequently seen conditions in 
township health centres and village clinics reported by 
either community dwellers24 or rural PHC clinicians 
(online supplementary appendix 1) from which the 
committee will select.
VP case design
The 10 selected VP cases will then be constructed indi-
vidually by 10 case-specific development teams (figure 2). 
These teams consist of one condition expert from the rele-
vant specialty of a tertiary teaching hospital who will be 
responsible for drafting the VP case; an evidence-synthesis 
group involving epidemiologists and evidence-based 
researchers who will search and synthesise evidence 
about the selected condition for the condition expert 
to work on; a clinical consensus group which consists of 
several condition-related clinical experts who will review 
the corresponding case from a scientific perspective; an 
overall all-condition shared context-expert panel, which 
includes clinicians and health managers from commu-
nity health centres, township health centres and village 
clinics, who will review the contextual appropriateness of 
the cases for the rural PHC setting and a case coordinator 
who will coordinate development of each case.
Each VP case will be structured into five domains—
medical history, physical examination, laboratory and 
imaging studies, diagnosis and management and treatment 
plan—to simulate real-life clinical scenarios.11 18 The struc-
tured VP cases will permit the examinee’s performance in 
each domain to be evaluated and for performance scores 
Figure 1 Seven sample provinces in China referencing countries of equivalent life expectancy in parentheses.
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to be aggregated across conditions. In addition to these 
five condition-related domains, another practice contex-
tual adjustment will be built into each case to consider 
medical resource constraints in rural practices (eg, avail-
ability of basic medical equipment and medicines).
Scoring criteria
Care quality scoring criteria will be developed for each VP 
case. These criteria include process quality, the accuracy of 
diagnosis and the appropriateness of the treatment and manage-
ment plan.3 4 Process quality will be evaluated in refer-
ence to a clinical process checklist (to be detailed later) 
including all necessary questions that should be asked 
and physical examinations that should be performed by 
clinicians, together with redundant or even potentially 
harmful practices. Diagnoses will be rated as correct, 
partially correct or incorrect based on predetermined 
standards. The treatment and management plan will be 
considered appropriate if the clinician prescribes any of 
the correct medications or refers the patient to a high-
er-level physician depending on the VP case.
In addition, cost of care and time-spent per encounter will 
also be recorded. Patient costs will cover medication fees 
and clinic fees charged per case. In order to link clini-
cian reaction time to each domain and to impose the 
temporal constraints seen in real clinical practices, the 
entire clinician-VP interaction process will be timed. This 
will include time spent on taking history, conducting 
physical examinations, prescribing drugs and treatments 
and any interruptions.
A systematic evidence-based approach will be adopted 
to developing the scoring checklist for the treatment and 
management plan (online supplementary appendix 2). 
Briefly, the evidence-synthesis group will systematically 
search and extract condition-specific checklist items and 
standards from clinical guidelines, reputable textbooks 
and systematic reviews, among others, in that order. The 
quality of the evidence will then be rated by the Appraisal 
of Guidelines for Research & Evaluation II (AGREE II)25 
or the revised Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS-2) according to its type.26 Afterwards, 
the clinical consensus group and the contextual-expert 
panel will review and revise initial standards using a 
Delphi process.27
VP case external review
To validate the content of VP cases, an independent 
expert panel of physicians, general practitioners and 
rural PHC clinicians who otherwise are not involved in 
the study, will be convened to review the cases for content 
accuracy and appropriateness. The content validation 
involves qualitative and quantitative phases. In the quali-
tative phase, the expert panel will be required to evaluate 
the cases with respect to the following: overarching assess-
ment goal, representativeness of the goal and test items 
to each domain, the logical relationship of the content 
tested and the appropriate wording, grammar, under-
standability and relevance to the rural PHC context. The 
panel will also record their suggestions, if any, next to 
each item. Modified VP cases will then be given back to 
the expert panel for quantitative evaluation. They will be 
asked to assess the cases for simplicity and clarity as well 
as necessity and relevance to the assessment, using a four-
point Likert scale ranging from 1 (the lowest) to 4 (the 
highest). The content validity index will be computed for 
each domain and for the entirety of VP cases.28
technical implementation
Revised VP cases will be implemented on CureFUN, an 
existing smartphone-based training platform using VPs 
with special customisations and set-up to suit the assess-
ment purpose. A live demonstration of a simplified VP 
Figure 2 Virtual patient case development team role and responsibilities.
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can be accessed from http://www. curefun. com/ zhiqu_ 
front/ www/ experience/ experience. html#/ caseList and 
is also illustrated in online supplementary appendix 3. 
The smartphone-based VP assessment tool will present 
interactive clinical scenarios and will automatically record 
each examinee’s diagnosis pathway and grade it against 
the scoring criteria (figure 3).
Feasibility study
Before a full-scale validation study, a feasibility study with 
30% of the validation study sample (see study sample 
section) will be conducted to test the VP assessment tool’s 
usability, accessibility and stability, particularly in remote 
village clinics with weak phone connectivity. Selected clini-
cians will be instructed to individually attempt two random 
VP cases within a given time, using their own smartphone 
devices from their workplace. Clinicians without a smart-
phone will be given a temporary device on which the 
customised CureFUN applications will be preinstalled. 
Clinicians’ willingness to participate and adherence to 
the VP-based tests (eg, percentage completing VP cases, 
score of the assessment and number of attempts made at 
each case per person) will be automatically recorded. On 
completion of the cases, participants will be asked to fill 
in a five-point Likert-scale questionnaire regarding their 
Figure 3 Main components of smartphone-based virtual patient programme.
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subjective attitude towards the simulator VP experience 
(with 1 being the most negative response and 5 being the 
most positive), regarding ease of use, their experience 
of the assessment process and outcome, realism, device 
competence, accessibility and other general comments. 
These results will be used to determine the face validity 
of the VP cases, with scores calculated by multiplying 
frequency (%) by positive evaluations (3–5); and scores 
no less than 1.5 are considered acceptable.29
Validation of VP as a quality assessment tool
Study design
The prospective validation study is a nationwide multi-
centre study with two main purposes: (1) to assess the 
criterion validity of the VP-tool in assessing the quality of 
primary healthcare, by analysing its measurement concor-
dance against the standard USP measure and (2) to test 
the reliability of the VP tool, by examining its internal 
consistency and the stability of repeated VP assessments 
on the same subjects.
Study sample
From each of our seven sample provinces, two counties 
will be selected with sufficient variations in socioeco-
nomic conditions, demographics and disease burdens 
between them while also approximating the provincial 
condition in general. Within each county, the govern-
ment registry of all township health centres and village 
clinics will serve as our sampling frame, which will include 
(1) licensed practicing physicians, (2) clinicians who 
have not been licensed but are providing clinical services 
under the supervision of licensed physicians at township 
health centres as well as (3) full-time or part-time village 
clinicians. Clinicians visiting on a temporary basis (often 
senior clinicians sent by higher level medical institutions 
to support the development of township health centres), 
nurses and allied health workers without prescription 
privileges will be excluded.
The sample size calculation is based on individual VP/
USP-clinician encounter and ensures sufficient power 
to detect variations at individual case level per county. 
For village clinics, one VP/USP case will be examined 
at a time to minimise the detection of USPs. Assuming a 
5% type I error and 80% power, to determine whether a 
moderate concordance correlation coefficient30 of 0.9031 
between VP and USP differs from zero, seven paired VP/
USP-clinician encounters will be required for each of the 
10 cases per county. As a stratified sampling strategy will 
be deployed that first samples townships and then villages 
from each township, sample size calculations need to take 
into account the design effect. Assuming an intraclass 
correlation of 0.05 and six village clinics per township, 
then nine paired VP/USP-clinician encounters is needed. 
These nine paired VP/USP-clinician encounters will be 
assigned to three township health centres and six village 
clinics using probability proportional to size. These nine 
paired VP/USP-clinician encounters will be assigned to 
township health centres and village clinics based on the 
ratio of the total number of clinicians at township health 
centres to the total number of village clinicians for each 
county. There are 1260 VP/USP-clinician encounters 
across our 7 study provinces for all 10 VP cases. Figure 4 
shows the sampling process and study flow for one VP 
case using Guizhou Province (Danzhai County) as an 
example.
Criterion validity
Criterion validity32 of the VP to assess quality of care will 
be evaluated primarily by its measurement concordance 
against the USP measure as the recognised gold standard33 
for assessing quality of care in practice. The USPs will be 
developed in a related study, sharing the development teams 
for VP and a similar development process. The method of 
fielding USPs in rural China will follow a similar approach 
to those of the previous USP study in rural China.3 Identical 
quality scoring criteria, described above, will be applied to 
scores. Each selected clinician will first see a USP (to avoid 
the practice effect due to the USP’s unannounced feature) 
and then complete a smartphone-based VP assessment of 
the same condition. The clinician to be assessed will be 
randomly selected onsite by the USP from any on-duty 
clinicians on the day of the USP visit to the sampled town-
ship health centre and village clinics. This situation would 
especially apply to township health centres, as most village 
clinics have only one clinician (note: Chinese patients 
normally see their primary care clinicians as a walk-in 
patient and appointments are seldom needed). To record 
USP-clinician interactions, USPs will complete checklists 
immediately after their visit and retain their prescription 
and the fee charge slips provided by the clinician. A week 
after the USP clinic visit, clinicians will be assigned a smart-
phone-based VP assessment, which will consist of an initial 
demonstration VP case to allow the clinician to familiarise 
themselves with how the system operates and then the 
test VP case of the same USP condition. The VP-clinician 
interactions, drugs dispensed and fees charged will all be 
recorded automatically by the online assessment system.
The concordance of the two USP and VP assessments 
will then be analysed by Lin’s concordance correlation 
coefficient (rc)
30 for continuous process quality scores, fees 
charged (yuan) and time spent (min) and the Kappa statistic34 
for dichotomous diagnoses and treatment & management 
measures. rc evaluates how close pairs of observation fell on 
a 45° line (the perfect concordance line) through the origin 
in addition to their correlation. Kappa measures agreement 
in assessment beyond what is expected by chance alone. In 
addition, for continuous measures, a Bland-Altman plot will 
also be used to visualise the concordance.35 36 For dichoto-
mous measures, we will analyse their sensitivity (ie, strength 
to detect correct diagnosis, treatment plan, among others) 
and specificity (ie, strength to detect incorrect diagnosis, 
treatment plan, among others) using USP as the reference.
Reliability
To establish test-retest reliability, clinicians previously being 
assessed by VPs will be instructed to retake the same VP tests 
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4 weeks after their last assessment. The second VP test is set 
1 month later than the first to reduce the practice effect,37 
assuming the clinician’s general medical knowledge 
remains constant.32 The concordance of the two repeated 
tests indicates the stability of the VP assessment tool.32 
Similar concordance measures (ie, rc for continuous and 
Kappa for dichotomous measures) as described above will 
be used. Internal consistency, the intercorrelation of scores for 
process quality indicators, will be computed by Cronbach’s 
alpha coefficients (α),38 with α>0.7 representing acceptable 
reliability.39 Table 2 summarises the validity, reliability and 
feasibility measures that will be examined in our study.
Patient and public involvement
We will seek feedback from clinicians and patient repre-
sentatives in the feasibility study and use their feedback to 
refine the VP cases. Our USPs will be lay people trained 
to portray patients and assess care quality based on their 
interactions with clinicians. Our scoring criteria thus are 
also patient-centred. Furthermore, all participants will be 
acknowledged for their involvement in the study and will be 
provided with a final summary report of the study outcomes 
and will have free access to the VP training website. All 
published results will be publicly available.
EthICs And dIssEMInAtIon
Informed consent will be obtained from all clinicians 
participating in the VP tests. However, to reduce participa-
tion bias due to self-selection,40 our IRB has approved the 
implementation of USP without prior informed consent 
from the individual participants, on the condition that 
involved clinicians will be fully deidentified and all analyses 
will only be conducted at the population level.40 Study data 
will be securely stored and only deidentified information 
Figure 4 Sampling and study process for one VP case in Danzhai County, Guizhou Province.
 o
n
 28 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020943 on 11 July 2018. Downloaded from 
8 Liao J, et al. BMJ Open 2018;8:e020943. doi:10.1136/bmjopen-2017-020943
Open access 
will be used for analysis. We will seek to publish study find-
ings in peer-reviewed journals and produce reports to 
inform health authorities. The tools and technology devel-
oped in this study will be freely available to other LMICs for 
research purposes.
dIsCussIon
To the best of our knowledge, this is the first study validating 
VP as a quality assessment tool in rural primary healthcare 
centres. This study follows an evidence-based approach to 
develop VP cases and scoring criteria, implements them on 
a widely accessible platform (ie, a smartphone) and system-
atically validates the VP assessment tool via a cross-national 
multicentre study representing rural PHCs over a wide 
range of geographic areas with distinct life expectancies 
and economic development levels. The VP assessment tool’s 
accessibility, flexibility and scalability give it good potential 
to be easily adapted to other LMICs.
VP has mainly been used in medical education to train 
and test critical thinking,18 41 42 and until recently few 
studies have applied the method in a practice setting to 
influence health provider behaviour and improve care 
quality.43 44 As an extension, we propose to validate VP as a 
quality assessment tool delivered via widely accessible smart-
phones. Nevertheless, it is to be noted that given its simu-
lated nature, the VP-test theoretically may never completely 
bridge the ‘know-do’ gap. The validation study is thus essen-
tial to quantify the concordance/discordance between 
VP-based and USP-based quality assessments. Our study will 
generate firsthand empirical evidence contributing to the 
understanding of the ‘know-do gap’5 45 and shed light on 
circumstances that cannot be tested by USPs.
A limitation of the study, however, is that, in order to test 
the validity of VP against USP as the reference standard, 
we restrict the selection of VP cases to those that can be 
simulated by USP. This conservative first step will neverthe-
less allow us to examine the extent to which VP can reflect 
care quality, and a follow-up study will then explore the 
full potential of the VP in assessing quality of care. Further, 
the two purposely selected counties for each province may 
not represent the provincial conditions entirely, although 
we will make every effort to consider provincial represen-
tation when selecting counties. Third, while the validation 
study is exclusively conducted on PHCs in rural China, the 
Table 2 Main validation domains of the study
Domain Indicator
Data collection
Statistical analysisPhase Method
Content validity Content validity 
index
VP case 
review
Evaluations by an expert panel 
after reviewing VP cases, 
measured by a 4-point Likert 
scale (1=lowest, 4=highest).
CVI for VP case and for specific VP 
domain will be computed, where 
CVI=number of raters giving a rating of 
3 or four divided by the total number of 
raters.
Feasibility Willingness to 
participate;
Adherence rate
Feasibility 
study
The subsample of clinicians’ 
interactions with the two VP 
cases will be recorded by the 
online assessment
Willingness to Participate=clinicians taking 
the VP tests divided by the percentage 
of clinician selected Adherence 
rate=clinicians completed two VP cases 
divided by the percentage of clinicians 
taking VP tests
Face validity Satisfying score Clinicians’ subjective attitude 
towards the VP test experience 
measured by a 5-point Likert 
scale (1=most negative, 
5=most positive).
Satisfying score for VP case and 
for specific aspects (eg, usability, 
accessibility, etc) will be computed, 
where satisfying score=frequency multiply 
by positive evaluations (3–5) and 
scores≥1.5 are considered acceptable.
Criterion validity Concordance 
correlation 
coefficient (rc);
Kappa statistic
Validation 
study
The same clinician receives a 
USP visit and a VP test for a 
matching condition. The USP-
clinician interaction is evaluated 
by the USP using the checklist, 
including fees and time per visit; 
while VP-clinician interaction is 
graded by the system.
The concordance of VP-test scores 
against USP-test score (gold standard) 
or two-repeated VP-tests will be 
examined by rc for continuous process 
quality scores, fees charged (yuan) 
and time spent (min) and Kappa for 
dichotomous diagnoses and treatment 
and management measures.
Test-retest 
reliability
Repeat VP-tests on the same 
clinician in a month
Internal 
consistency
Cronbach’s alpha 
coefficient (α)
VP-test scores on a single 
occasion
Intercorrelation of scores for process 
quality indicators with α>0.7 is acceptable.
CVI, content validity index; VP, virtual patient.
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extent to which the VP assessment tool can be transported 
to other LMICs remains to be evaluated. Nonetheless, by 
implementing the study in a diverse set of Chinese prov-
inces may improve the generalisability of our study consid-
ering the comparable life expectancies of LMICs and these 
provinces.
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